The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

Drug Intelligence & Clinical Pharmacy: Vol. 15, No. 5, pp. 386-388.
© 1981 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Matzke, G.
Right arrow Articles by Sawchuk, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Matzke, G.
Right arrow Articles by Sawchuk, R.

Research Articles

Elevated serum phenytoin concentrations in a uremic patient when measured by enzyme-multiplied immunoassay

GR Matzke and RJ Sawchuk

A patient with chronic renal failure did not respond to "therapeutic" serum phenytoin concentrations as measured by enzyme-multiplied immunoassay (EMIT). Her seizure disorder was not controlled despite phenytoin concentrations of 25-35 micrograms/ml. When her serum samples were reassayed by high pressure liquid chromatography and gas-liquid chromatography, the phenytoin serum concentrations were found to be approximately 1/2 of the previously reported values, that is, 16.0 micrograms/ml vs. 33 micrograms/ml. The precise reason for this discrepancy is currently unknown. Our findings suggest that the EMIT assay may yield falsely elevated serum phenytoin concentrations in uremic subjects.




homecopy help contact us subscription past issues search current issue
Copyright © 1981 by Harvey Whitney Books Company.